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ABSTRACT 
 
Background: Uterine cervical cancer is one of the main causes of female death related to 
cancer. Neoadjuvant chemotherapy aims to reduce tumor mass to allow radical surgery. HIF-
1α is thought to have a key role in the development of cancer and the main target for 
chemoprevention.  
Objective: This study aims to prove the effect of neoadjuvant chemotherapy on HIF-1α 
expression in uterine cervical cancer as an assessment parameter for chemotherapy response. 
Subjects and methods: The study was carried out in the Department of Obstetrics and 
Gynecology and the Pathology Department of Anatomy Dr. Moewardi - Faculty of Medicine, 
Sebelas Maret University, Surakarta. Thirty (30) cervical cancer samples that met the inclusion 
and exclusion criteria were examined for HIF-1α expression before and after giving 3 times 
neoadjuvan chemotherapy. Examination using immunohistochemical methods. Data analysis 
using t test.  
Results: Mean HIF-1α expression before administration of neoadjuvant chemotherapy 5.10± 
1.174 cell/field, after administration of neoadjuvant chemotherapy 4.00±1.174 cell/field with 
p=0.001.  
Conclusion: Neoadjuvant chemotherapy has an effect on reducing HIF-1α expression in 
uterine cervical cancer. 
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BACKGROUND 
Cervical cancer of the uterus is the primary 
malignancy of the cervix which is in the 
portion and cervical canal (Andrijono, 
2016). According to WHO, cervical cancer 
ranks second after breast cancer. Around 
the world more than 200 thousand people 
die each year from cervical cancer (World 
Health Organization, 2014). In Central Java 
the incidence of cervical cancer is more 
than 2000 cases and in Dr. Moewardi 
Hospital Surakarta in 2013 there were more 
than 1700 cases of cervical cancer patients 
(Wardani, 2014).  
Neoadjuvant chemotherapy aims to 
allow surgical action on cervical cancer 
which has a major obstacle to primary 
lesions, chemotherapy is expected to reduce 
tumor mass so as to allow radical surgery 
(Berman, 2015). The success of neoadju-
vant chemotherapy is influenced by the 
type of chemotherapy given and gives a 
better response if given in combination 
with minimal risk of resistance (Andrijon0, 
2016). Cisplatin and Paclitaxel chemothe-
rapy regimens are a combination of drugs 
that have a rapid, free-survival therapy 
response and can improve quality of life. 
The combination of Carboplatin and 
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Paclitaxel is easy to supply, administration 
and tolerance is also the first choice in 
chemotherapy (Koh, 2016). The chemothe-
rapy combination is more sensitive in 
cervical cancer patients with squamous cell 
types than other types such as adenocarci-
noma and clear cell (Chen et al., 2017). 
Hypoxia inducible factors-1α (HIF-1α) 
is a transcription factor that responds to 
tissue hypoxia that occurs in the stages of 
carcinogenesis. Cells that experience hypo-
xia stimulate the secretion of HIF-1α in 
cervical cancer, then HIF-1α stimulates the 
expression of various genes that are 
important in the development of cancer. 
This study aims to determine the 
effect of neoadjuvant chemotherapy on the 
expression of HIF-1α in uterine cervical 
cancer. 
 
SUBJECTS AND METHOD 
This study is a prospective cohort study 
conducted on early stage cervical cancer 
patients given Paclitaxel-Carboplatin neo-
adjuvant chemotherapy 3 times. The study 
was conducted in the Department of Obste-
trics and Gynecology and the Pathology 
Section of the Anatomy of the Dr. Moe-
wardi - Faculty of Medicine, Sebelas Maret 
University Surakarta in November 2017 - 
April 2018. The research subjects were 
cervical cancer patients who came to the 
Gynecology Oncology Clinic, as well as in 
the Nursing Room of Dr. Hospital. 
Moewardi, Surakarta. The inclusion criteria 
were early stage IB2 and IIA2 cervical 
cancer patients with a bulky tumor (dia-
meter of cervical lesion >4 cm) and had 
never received treatment. The exclusion 
criteria are “there are medical disorders/ 
systemic diseases that are dangerous such 
as hypertension, thromboembolism and 
heart disease or contra indications of 
chemotherapy and surgery” and “there are 
tumors/malignancies in addition to uterine 
cervical cancer” (Stefani, 2016). 
The dose of Paclitaxel used is 175mg / 
m2. The dose of Carboplatin used is 5 
(AUC) x (25 + GFR). Chemotherapy is 
given 3 times at intervals between chemo-
therapy for 3 weeks. 
Examination of HIF-1α expression in 
cervical cancer before and after receiving 
neoadjuvant chemotherapy employed HIF-
1α antibody reagent from Abcam Cam-
bridge Science Park, UK in 2012. Painting 
was done using Avidin Biotin Complex 
from Biocare Medical, LLC, Concord, USA. 
The unit of measurement is the sum of the 
number of colored field perceptions and the 
percentage of their intensity. 
This study employed the immuno-
histochemistry method. Evaluating of the 
quality (intensity) of immunoreaction and 
combining the examination of the intensity 
score with the quantity (fraction) of cells 
stained to produce a semiquantitative 
scoring system were done. The system is 
intended to reduce the subjectivity of 
examiners.  
This study was conducted by two 
examiners by assessing how to read accord-
ing to Birner et al (2000) from all fields of 
view using a Olympus Cx 21 microscope 
with a 400x microscope (10x ocular lens, 
40x objective lens). First, the reagent area 
is seen in color, if the total area is 11-50%, 
the score is 2, 51-80% is given a score of 3, 
>81% is given a score 4. Then the intensity 
of the color of the reagent is assessed. If the 
weak intensity is given a score of 1, the 
intensity is being given a score of 2, the 
intensity is given a score of 3. Then both the 
results of the area/percentage and intensity 
are added together. Negative expressions 
are said if <10% are positive cells, value 3 
for weak expressions, 4-5 values for mode-
rate expressions, and values 6-7 for strong 
expressions (Birner et al., 2000). 
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The research ethics include informed 
consent, anonymity, confidentiality and 
ethical conduct. Ethical Feasibility of this 
research was carried out in dr. Moewardi 
hospital, Surakarta, with no. Ethical 
feasibility: 708 / IX / HREC / 2018. 
 
RESULTS 
The characteristics of the research subjects 
in table 1 show that the majority of samples 
were 40-60 years old (73.3%) and at least 
<40 years (16.7%); Most of them are 
elementary school graduates of 15 samples 
(50.0%) and at least 1 sample diploma 
(3.33%); Parity 0-2 is the highest 19 
samples (63.33%), the lowest parity> 4 is 1 
sample (3.33%); Most stage IIA2 is 27 
samples (90.0%), at least IB2 is 3 samples 
(10.0%). The highest histological sample of 
squamous cell carcinoma was 25 samples 
(83.33%) and the lowest was 5 samples 
(16.67%) histology in addition to squamous 
cell carcinoma. This figure shows the 
histopathological type of squamous cell 
carcinoma more dominant than other cell 
types such as adenocarcinoma and clear 
cell. 
Table 1.  Sample Characteristic 
Charactersitics  n % 
Age   
< 40 years old 5 16.7 
40-60 years old 22 73.3 
> 60 years old 3 10.0 
Education 
 
 
Elementary school 15 50.0 
Junior high school 4 13.3 
Senior high school 8 26.7 
Diploma 1 3.3 
Bachelor 2 6.7 
Parity 
 
 
0 – 2 19 63.33 
3 to 4 10 33.33 
> 4 1 3.33 
Stage of cancer 
 
 
I B2 3 10.0 
II A2 27 90.0 
Histology 
 
 
KSS 25 83.33 
Non KSS 5 16.67 
HIF-1 expression in early cervical 
uterine cancer patients before and after 
neoadjuvant chemotherapy paclitaxel-
carboplatin was described in graph 1 where 
HIF-1 expression was lower after neo-
adjuvant chemotherapy. 
 
 
Figure 1. Expression of HIF--1 Pre 
and Post Chemotherapy Neoadjuvan 
Paclitaxel - Carboplatin  
 
In the normality test of the expression of 
HIF-1α by using the normal distribution 
test (Shapiro-Wilk) and after adminis-
tration of neoadjuvant chemotherapy with 
the results of the normality test described 
that the data was not normally distributed. 
The value of p = 0.004 for the results 
before chemotherapy and p<0.001 for the 
results after chemotherapy. 
The mean of HIF 1  tissue expression 
before the administration of neoadjuvant 
chemotherapy was higher (mean= 5.10; 
SD= 1.12) cells compared to after neoadju-
vant chemotherapy (mean= 4.00; SD= 1.17) 
cells with p=0.001. 
Table 3. Mean difference test for 
HIF1  expression in tissues before 
and after administration of neo-
adjuvant chemotherapy 
Group N 
Expression 
average 
HIF-1 
(cells) 
p 
Before 
chemotherapy 
30 5.10±1.13 0.001 
After 
chemotherapy 
30 4.00±1.17  
 
The expression of HIF-1 in the 
cytoplasm provided microscopic dark 
Indonesian Journal of Medicine (2018), 3(2): 109-114 
https://doi.org/10.26911/theijmed.2018.03.02.08 
112   e-ISSN: 2549-0265 
brown color images by using immuno-
histochemical analysis. 
 
Figure 2. HIF-1α Expression 
Information : 
A. Before conducting neoadjuvant chemo-
therapy. The black arrow showed a picture 
of strong expression on the core with dark 
brown color. The red arrow showed strong 
expression on the cytoplasm with dark 
brown color. Yellow arrows indicated cells 
that did not express HIF-1α, a "hello" 
picture. B. After administration of neoadju-
vant chemotherapy which shown by the red 
arrow was the expression of HIF-1α in the 
cytoplasm after the administration of light 
brown color neoadjuvant chemotherapy. 
Brownish color was a reaction between 
staining with 1-α HIF antibody and hema-
toxylin eosin. Examination using Cx 21 
Olympus microscope with 400 x 
magnification. 
 
DISCUSSIONS 
The expression of HIF-1α in uterine cervical 
cancer has been observed in 30 study 
samples before and after neoadjuvant che-
motherapy according to immunohistoche-
mical staining based on an assessment 
according to Birner et al. The analysis 
showed a significant decrease in the rate of 
HIF-1α expression in uterine cervical 
cancer after administration of neoadjuvant 
chemotherapy (p=0.001).  
In cervical cancer, the expression of 
HIF-1α was increased which played an 
important role in the effects of metabolism, 
angiogenesis, metastasis, and inflammation 
in cervical cancer cells. Expression of HIF-
1α in solid tumors has been detected in 
hypoxic cell perinecrotic regions (Melillo, 
2014). Angiogenesis in cervical cancer has 
been shown to be induced by HIF-1α 
through activation of HIF-1 and VEGF 
target gene expression. In hypoxic condi-
tions, there was aggressiveness in tumor 
growth. Activation of the HIF-1α pathway 
in cancer tissue specimens has been 
discussed in several immunohistochemical 
studies. In 2012, a study by Dos Santos et al 
regarding the expression of HIF-1α in 
squamous cell carcinoma in the oral cavity 
showed that strong HIF-1α expression was 
associated with a high rate of disease 
recurrence. Tumors with high HIF-1α 
expression activate transcription of genes 
related to angiogenesis, including VEGF, so 
that they can be predictors of the success 
rates of radiotherapy or chemotherapy.  
The effect of neoadjuvant chemo-
therapy on high expression of HIF-1α in 
cervical cancer, chemotherapy caused more 
death of neoplastic cells, which can reduce 
the size of cervical lesions and improve 
vascularization in cancer cells because 
tumors have irregular vascularization and 
O2 cellular imbalance occurred, so that 
after administration of neoadjuvant chemo-
therapy, it resulted in high oxygenation of 
cervical cancer tissue and indirectly 
decreased the HIF-1α expression (dos 
santos et al., 2012). 
Paclitaxel and carboplatin were used 
in this study because in general, tumors 
that experienced hypoxia were resistant to 
conventional radiotherapy and chemo-
therapy with high levels of aggressiveness. 
Oxygen homeostasis in cells and hypoxic 
stress occurred mostly through the HIF 
pathway. However, dysregulation on the 
HIF pathway was related to poor outcomes 
if it used conventional therapy. This was 
because the hypoxic cell state was a 
reaction of a cancer cell to maintain the 
B A 
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survival of cancer cells, became aggressive, 
and protection against anti-cancer therapy. 
Currently, therapy was focused on reactive 
oxygen substances that can increase the 
death of DNA in damaged cells. Therefore, 
the target of therapy was on the HIF path-
way with therapeutic strategies on hypoxia 
and angiogenic tumors by using combina-
tion chemotherapy of paclitaxel and carbo-
platin to inhibit HIF-1α which has been 
shown to be clinically beneficial and result-
ing in a decrease in HIF-1α expression 
(Poon, Harris and Ashcroft, 2009). 
The expression of HIF-1α in cervical 
cancer tissue has decreased significantly 
after administration of neoadjuvant chemo-
therapy in line with research by Birner et al. 
(2000) where hypoxia increased radiation 
resistance and depend on HIF-1α by 
increasing VEGF expression and inhibiting 
p53 expression.  
Previous studies of breast cancer 
showed that positive expression of HIF-1α 
in neoadjuvant chemotherapy where the 
value of HIF-1α expression in breast cancer 
tissue was lower after chemotherapy than 
before chemotherapy with (Ruihua, Yong-
qiang and Zongzhu, 2017). Based on this 
study and supported by previous studies, it 
showed that the level of HIF-1α protein can 
be used as a prognostic marker in various 
cancers. 
In uterine cervical cancer patients 
with high HIF-1α expression which has a 
poor prognosis, with a 73% survival rate, 
and with low HIF-1α expression, it has 93% 
survival rate. These data indicated that 
HIF-1α was needed at the initiation phase 
of cancer development and played an 
important role in the development and 
ability of metastasis(Onnis, Rapisarda and 
Melillo, 2009). 
 
Based on the results of this study, it 
can be concluded that the administration of 
neoadjuvant chemotherapy has an effect on 
reducing the expression of HIF-1α in 
uterine cervical cancer patients. 
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